Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6948864 | 0.75 | NPC1 (0.48) | RAB9ASMN1; SMN2ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL4142949 | 0.75 | ALDH1A1 (0.47) | ALDH1A1HPGDMAPK1NPC1 | |
| SCHEMBL16198631 | 0.73 | RAB9A (0.44) | RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL28712647 | 0.72 | HSD17B10 (0.43) | SMN1; SMN2ALDH1A1HPGDMAPK1NPC1 | |
| SCHEMBL15170828 | 0.72 | RAB9A (0.38) | RAB9ASMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL8924195 | 0.71 | — | — | |
| SCHEMBL6951940 | 0.70 | TRPV1 (0.44) | SMN1; SMN2ALDH1A1HPGDMAPK1NPC1 | |
| SCHEMBL6579797 | 0.70 | MAPK1 (0.38) | SMN1; SMN2ALDH1A1HPGDMAPK1NPC1 | |
| SCHEMBL9441451 | 0.70 | — | — | |
| SCHEMBL3244004 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20150119571-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-30 | — | — | US | disclosed |
| US-8871792-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119571-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RAB9A 812/4885SMN1; SMN2 1013/4885ALDH1A1 2394/4885 |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RAB9A 812/4885SMN1; SMN2 1013/4885ALDH1A1 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.